 |
|
Dosing With 5% Imiquimod Cream 3 Times per Week for the Treatment of Actinic Keratosis
Results of Two Phase 3, Randomized, Double-blind, Parallel-Group, Vehicle-Controlled Trials
Neil Korman, MD, PhD;
Ron Moy, MD;
Mark Ling, MD, PhD;
Robert Matheson, MD;
Stacy Smith, MD;
Scott McKane, MS;
James H. Lee, MD, PhD
Arch Dermatol. 2005;141:467-473.
Objective To evaluate the efficacy and safety of 5% imiquimod cream compared with vehicle in the treatment of actinic keratosis (AK).
Design Two phase 3 randomized, double-blind, parallel-group, vehicle-controlled studies.
Setting Twenty-six ambulatory care offices, including dermatologists in private practice or research centers.
Patients Four hundred ninety-two patients, 18 years and older, with 4 to 8 AK lesions in a 25-cm2 treatment area on the face or the balding scalp were randomized; an additional 162 patients underwent screening but were ineligible.
Interventions Patients applied 5% imiquimod (Aldara) or vehicle cream to the treatment area once daily, 3 times per week, for 16 weeks, followed by an 8-week posttreatment period.
Main Outcome Measurements Complete clearance rate (proportion of patients at the 8-week posttreatment visit with no clinically visible AK lesions in the treatment area), partial clearance rate (proportion of patients at the 8-week posttreatment visit with a  75% reduction in the number of baseline AK lesions in the treatment area), and frequency and severity of adverse events and local skin reactions were measured.
Results Complete and partial clearance rates for imiquimod-treated patients (48.3% and 64.0%, respectively) were clinically and statistically significantly higher than for vehicle-treated patients (7.2% and 13.6%, respectively). The median percentage reduction of baseline lesions was 86.6% for the imiquimod-treated group and 14.3% for the vehicle-treated group.
Conclusion The 5% imiquimod cream dosed 3 times weekly for 16 weeks is safe and effective for the treatment of AK.
Author Affiliations: Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio (Dr Korman); Skin Cancer and Dermatologic Surgery Medical Group and Westwood Ambulatory Center, Los Angeles, Calif (Dr Moy); MedaPhase, Inc, Newnan, Ga (Dr Ling); Oregon Medical Research Center, Portland (Dr Matheson); Therapeutics Inc, La Jolla, Calif (Dr Smith); and 3M Pharmaceuticals, St Paul, Minn (Mr McKane and Dr Lee).
RELATED ARTICLES
Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients: A Study of the Swedish Cohort With Regard to Tumor Site
Bernt Lindelöf, Henrik Dal, Katarina Wolk, and Niklas Malmborg
Arch Dermatol. 2005;141(4):447-451.
ABSTRACT
| FULL TEXT
Clinical Recognition of Actinic Keratoses in a High-Risk Population: How Good Are We?
Suraj S. Venna, Dennis Lee, Miguel J. Stadecker, and Gary S. Rogers
Arch Dermatol. 2005;141(4):507-509.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Smits et al.
The Oncologist 2008;13:859-875.
ABSTRACT
| FULL TEXT
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
Stary et al.
JEM 2007;204:1441-1451.
ABSTRACT
| FULL TEXT
Facial resurfacing for nonmelanoma skin cancer prophylaxis.
Hantash et al.
Arch Dermatol 2006;142:976-982.
ABSTRACT
| FULL TEXT
Imiquimod for Actinic Keratoses: When Red Is Good
Journal Watch Dermatology 2005;2005:5-5.
FULL TEXT
Imiquimod for Actinic Keratoses: When Red Is Good
JWatch General 2005;2005:10-10.
FULL TEXT
|
